Are inflammation and ossification on separate tracks in ankylosing spondylitis?

Joint Bone Spine

Volumn 75, Issue 5, 2008, Pages 520-522

  Claudepierre, Pascal ^a   Wendling, Daniel ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Ankylosing spondylitis; Disease progression; Imaging, medical; Ossification, pathologic; Pathophysiology; TNF alpha antagonists

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; ETANERCEPT; INFLIXIMAB; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; WNT PROTEIN;

ANKYLOSING SPONDYLITIS; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROTEIN INTERACTION; SPINE RADIOGRAPHY;

ANIMALS; ANTIRHEUMATIC AGENTS; DISEASE MODELS, ANIMAL; GUINEA PIGS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; MICE; OSSIFICATION, HETEROTOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 53349146398     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2008.04.006     Document Type: Editorial

References (22)

1. Kavanaugh A., Tutuncu Z., and Catalan-Sanchez T. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol 18 (2006) 347-353
2. Claudepierre P. Spondylarthrite ankylosante. In: Bardin T., and Orcel P. (Eds). Traité de thérapeutique rhumatologique (2007), Médecine Sciences Flammarion 512-522
3. Van der Heijde D.M., Landewé R.B., Ory P., et al. Two-year etanercept therapy does not inhibit radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 65 Suppl. 2 (2006) 81
4. Van der Heijde D., Landewe R., Deodar A., et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment not inhibited with infliximab. Ann Rheum Dis 66 Suppl. II (2007) 85
5. Wendling D., Toussirot E., Streit G., et al. Imaging study scores for ankylosing spondylitis. Joint Bone Spine 73 (2006) 655-660
6. Baraliakos X., Listing J., Rudwaleit M., et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 66 (2007) 910-915
7. Baraliakos X., Listing J., Brandt J., et al. Radiographic progression in patients with ankylosing spondylitis after 4 years of treatment with the anti TNF-α antibody infliximab. Rheumatology 46 (2007) 1450-1453
8. Wanders A., Heijde D., Landewé R., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheum 52 (2005) 1756-1765
9. Maksymowych W., Landewé R., Conner-Spady B., et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56 (2007) 1846-1853
10. Braun J., Landewé R., Hermann K.G., et al. Sustained reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 66 Suppl. II (2007) 64
11. Lories R.J., Derese I., De Bari C., et al. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 56 (2007) 489-497
12. Roux S., and Orcel P. Bone loss. Factors that regulate osteoclast differentiation: an update. Arthritis Res 2 (2000) 451-456
13. Francois R.J., Neure L., Sieper J., et al. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 65 (2006) 713-720 [Epub 2005 Oct 25]
14. Braun J., Bollow M., Neure L., et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38 (1995) 499-505
15. Archer J.R. Ankylosing spondylitis, IgA, and transforming growth factors. Ann Rheum Dis 54 (1995) 544-546
16. Claudepierre P., Rymer J.C., Authier F.J., et al. A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies. Br J Rheumatol 36 (1997) 400-401
17. Wendling D., Cedoz J.P., Racadot E., et al. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 74 (2007) 304-305
18. Lories R.J., Derese I., and Luyten F.P. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 115 (2005) 1571-1579
19. Canalis E., Giustina A., and Bilezikian J. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357 (2007) 905-916
20. Diarra D., Stolina M., Polzer K., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13 (2007) 156-163
21. Qian J., Xie J., Hong S., et al. DKK1 is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110 (2007) 1587-1594
22. Wanders A., Landewe R., Dougados M., et al. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?. Ann Rheum Dis 64 (2005) 988-994